Introduction
Acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) is a distinct subtype of AML characterized by features of prior myelodysplasia. It is associated with poor prognosis and often requires specialized treatment approaches. The World Health Organization (WHO) classifies AML-MRC separately due to its unique clinical and genetic characteristics.
Criteria for AML-MRC Diagnosis
AML-MRC is diagnosed when at least one of the following criteria is met:
- History of Myelodysplastic Syndrome (MDS) or Myelodysplastic/Myeloproliferative Neoplasm (MDS/MPN)
- Patients previously diagnosed with MDS who later develop AML are classified as AML-MRC.
- Dysplasia in ≥50% of Cells in at Least Two Lineages
- The presence of dysplasia in red blood cells, granulocytes, or platelets in more than half of the observed cells.
- Myelodysplasia-Related Cytogenetic Abnormalities
- Chromosomal abnormalities commonly associated with MDS, including:
- Deletion of chromosome 5q or 7q
- Monosomy 5 or 7
- Complex karyotypes (≥3 chromosomal abnormalities)
- Chromosomal abnormalities commonly associated with MDS, including:
Symptoms of AML-MRC
Patients with AML-MRC often present with:
- Fatigue and weakness due to anemia
- Increased infections due to low white blood cell counts
- Easy bruising and bleeding caused by thrombocytopenia
- Fever and weight loss
- Bone pain and enlarged spleen (in some cases)
Treatment Approaches
The treatment of AML-MRC is often more challenging due to its poor response to standard chemotherapy. Options include:
1. Intensive Chemotherapy
- Standard 7+3 regimen (Cytarabine + Anthracycline) may be used but is often less effective in AML-MRC.
- CPX-351 (liposomal daunorubicin and cytarabine) is FDA-approved for AML-MRC and has shown better outcomes.
2. Targeted Therapy
- Venetoclax (BCL-2 inhibitor) combined with low-dose chemotherapy is an option for older or unfit patients.
- Mutation-specific therapies, such as FLT3 inhibitors or IDH inhibitors, may be used if applicable.
3. Stem Cell Transplantation
- The only potentially curative option for AML-MRC.
- Best outcomes occur when performed after achieving remission.
4. Supportive Care
- Blood transfusions, antibiotics, and growth factors to manage complications.
- Palliative care in patients who cannot tolerate intensive therapy.
Prognosis
AML-MRC has a poorer prognosis than other AML subtypes due to its association with genetic abnormalities and chemotherapy resistance. However, treatment advances, such as CPX-351 and stem cell transplantation, have improved outcomes for some patients.
Conclusion
AML-MRC is a high-risk subtype of AML requiring specialized treatment strategies. Early diagnosis, personalized therapy, and consideration of stem cell transplantation are crucial in managing this aggressive form of leukemia.
